Renal kallikrein: A risk marker for nephropathy in children with sickle cell disease

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 3, 2006, Pages 147-153

  Bergmann, Shayla ^a   Zheng, Deyi ^b   Barredo, Julio ^a   Abboud, Miguel R ^a   Jaffa, Ayad A ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Albumin excretion rate; Hemoglobin; Nephropathy; Renal kallikrein; Sickle cell disease

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; HEMOGLOBIN; KALLIKREIN;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HEMOGLOBIN SC DISEASE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ADOLESCENT; ALBUMINS; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HEMOGLOBINS; HUMANS; KALLIKREINS; KIDNEY DISEASES; MALE; RISK FACTORS; SEX FACTORS;

EID: 33646906252     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000203722.91189.9d     Document Type: Article

References (37)

1. Wigfall DR, Ware RE, Burchinal MR, et al. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr. 2000;136:749-753.
2. McBurney PG, Hanevold CD, Hernandez CM, et al. Risk factors for microalbuminuria in children with sickle cell anemia. J Pediatr Hematol/Oncol. 2002;24:473-477.
3. Faulkner M, Turner EA, Deus J, et al. Severe anemia: a risk factor for glomerular injury in sickle cell disease. J Natl Med Assoc. 1995;87:209-213.
4. Pham PT, Pham PT, Wilkinson AH, et al. Renal abnormalities in sickle cell disease. Kidney Int. 2000;57:1-8.
5. Guasch A, Cua M, You W, et al. Sickle cell anemia causes a distinct pattern of glomerular dysfunction. Kidney Int. 1997;51:826-833.
6. Dharnidharka VR, Dabbagh S, Atiyeh B, et al. Prevalence of microalbuminuria in children with sickle cell disease. Pediatr Nephrol. 1998;12:475-478.
7. Saborio P, Scheinman JI. Disease of the month: sickle cell nephropathy. J Am Soc Nephrol. 1999;10:187-192.
8. Foucan L, Bourhis V, Bangou J, et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med. 1998;104:339-342.
9. Falk RH, Scheinman J, Phillips G, et al. Prevalence and pathological features of sickle cell nephropathy and the response to inhibition of angiotensin-converting enzyme. N Engl J Med. 1992;326:910-915.
10. Harvey JN, Jaffa AA, Margolius HS, et al. Renal kallikrein and the hemodynamic abnormalities of the diabetic kidney. Diabetes. 1990;39:299-304.
11. Harvey JN, Edmundson AW, Jaffa AA, et al. Renal excretion of kallikrein and eicosanoids in patients with type I diabetes: relationship to glomerular and tubular function. Diabetologia. 1992;35:857-862.
12. Jaffa AA, Rust PF, Mayfield RK. Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes. 1995;44:156-160.
13. Mayfield RK, Margolius HS. Renal kallikrein-kinin system relation to renal function and blood pressure. Am J Nephrol. 1983;1:145-155.
14. Chao J, Jin L, Chen LM, et al. Systemic and portal vein delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther. 1996;7:901-911.
15. The Diabetes Control and Complications. Trial Research Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
16. Barajas L, Powers K, Carretero D, et al. Immunocytochemical localization of renin and kallikrein in the rat renal cortex. Kidney Int. 1986;29:965-970.
17. Vio CP, Figueroa CD, Caorsi I. Anatomical relationship between kallikrein-containing tubules and the juxtaglomerular apparatus in the human kidney. Am J Hypertens. 1988;1:269-271.
18. Figueroa CD, Maclver AG, MacKenzie C, et al. Localization of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 1988;89:437-442.
19. Siragy HM, Jaffa AA, Margolius HS. Stimulation of renal interstitial kinins by sodium depletion. Am J Hypertens. 1993;6:863-866.
20. Siragy HM, Khalil T, Jaffa AA, et al. Sodium intake alters renal interstial bradykinin, prostaglandin-E2 and cGMP. Hypertension. 1994;23:1068-1070.
21. Siragy HM, Jaffa AA, Margolius HS. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. Hypertension. 1997;29:757-762.
22. Bascands JL, Pecher C, Cabos G, et al. B2-kinin receptor like binding in rat glomerular membranes. Biochem Biophys Res Comm. 1989;158:99-104.
23. Bascands JL, Pecher C, Rouaud S, et al. Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am J Physiol. 1993;264:F548-F556.
24. Edwards RM. Response of isolated renal arterioles to acetylcholine, dopamine and bradykinin. Am J Physiol. 1985;248:F183-F189.
25. Jong PE, Statius van Eps LW. Sickle cell nephropathy: new insights into its pathophysiology. Kidney Int. 1985;27:711-717.
26. Schmitt F, Martinez F, Brillet G, et al. Early glomerular dysfunction in patients with sickle cell anemia. Am J Kidney Dis. 1998;32:208-214.
27. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med. 1990;150:501-504.
28. Falk RJ, Jennette JC. Sickle cell nephropathy. Adv Nephrol. 1994;23:133147.
29. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG_KIDS study, a phase I/II trail. Blood. 1999;94:1550-1554.
30. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
31. Kichuk MR, Seyedi N, Zhang X, et al. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation. 1996;94:44.
32. Briner VA, Tsai P, Schrier RW. Bradykinin: potential for vascular constriction in the presence of endothelial injury. Am J Physiol. 1993;264:F322-F327.
33. Velarde V, Ullian ME, Morinelli TA, et al. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am J Physiol. 1999;277:C253-C261.
34. Naidu P, Velarde V, Kappler C, et al. Calcium and calmodulin mediate bradykinin induced mitogen activated protein kinase phosphorylation and c-fos induction in vascular cells. Am J Physiol. 1999;277:H1061-H1068.
35. Greene EL, Velarde V, Jaffa AA. Role of reactive oxygen species in bradykinin induced MAPK and c-fos induction in vascular cells. Hypertension. 2000;35:942-947.
36. Douillet CD, Velarde V, Christopher JT, et al. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-β and MAPK. Am J Physiol. 2000;279:H2829-H2837.
37. Strauss J, Zilleruelo G, Abitbol C. The kidney and hemoglobin S. Nephron. 1986;43:241-245.